Slide Show: Kidney Cancer

Slideshow

This kidney cancer slide show features images of chromophobe, papillary, and clear-cell renal cell carcinomas; as well as sarcomatoid, transitional cell, and small-cell carcinomas of the kidney.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
We are seeing that, in those patients who have relapsed/refractory melanoma with survival measured as a few weeks and no effective treatments, about a third of these patients will have a response.
We have the current CAR [T-cell therapies], which target CD19; however, we need others.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
Related Content
This is the first and only therapy that improved survival when used before and after standard of care surgery in patients who are cisplatin-ineligible with MIBC.

Enfortumab Vedotin/Pembrolizumab Improved Survival Vs Surgery in MIBC

Tim Cortese
August 12th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 12th 2025
Podcast
It was reported that though the treatment did not demonstrate statistical significance, it did yield a clinically meaningful improvement in PFS.

Novel Cancer Vaccine Combo Therapy Numerically Improves PFS in Melanoma

Tim Cortese
August 12th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 12th 2025
Podcast
The decision is based on phase 3 VERITAC-2 trial data showing a significant PFS improvement vs fulvestrant in ESR1-mutant ER+/HER2– breast cancer.

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2– Breast Cancer

Roman Fabbricatore
August 12th 2025
Article
Exercise significantly enhances cancer treatment outcomes, improving survival rates and quality of life for patients with colon cancer who have completed therapy.

New Colon Cancer Data Shows Importance of Exercise Therapy for Survival

Neil M. Iyengar, MD
August 12th 2025
Article